Key result
A 38-year-old man with COVID-19-associated post-infectious fulminant myocarditis was successfully bridged to heart transplantation using VA-ECMO support and fully recovered.
Case Report (n=1)
No
Heart transplantation can be a viable, life-saving intervention for patients with COVID-19-associated post-infectious fulminant myocarditis who are refractory to medical therapy and mechanical circulatory support.
Case of post-COVID fulminant myocarditis requiring transplant at day 11; hypothesis-generating for bridging and timing decisions.
Various clinical presentations of the 2019 coronavirus disease (COVID-19) have been described, including post-infectious acute and fulminant myocarditis. Here, we describe the case of a young patient admitted for COVID-19-associated post-infectious fulminant myocarditis. Despite optimal pharmacologic management, haemodynamic status worsened requiring support by veno-arterial extracorporeal membrane oxygenation. Emergent heart transplantation was required at Day 11 given the absence of cardiac function improvement. The diagnosis of post-infectious COVID-19-associated myocarditis was made from both pathologic examination of the explanted heart and positive SARS-CoV-2 serology.
No takes yet. Share an insight, caveat, or question.
Gaudriot et al. (2021) conducted a case report in COVID-19-associated post-infectious fulminant myocarditis (n=1). Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and heart transplantation was evaluated on Survival and recovery. A 38-year-old man with COVID-19-associated post-infectious fulminant myocarditis was successfully bridged to heart transplantation using VA-ECMO support and fully recovered.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: